A detailed history of Carlyle Group Inc. transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Carlyle Group Inc. holds 3,496,808 shares of PHAT stock, worth $26.2 Million. This represents 9.52% of its overall portfolio holdings.

Number of Shares
3,496,808
Previous 3,496,808 -0.0%
Holding current value
$26.2 Million
Previous $36 Million 75.53%
% of portfolio
9.52%
Previous 4.3%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 04, 2023

BUY
$7.28 - $14.32 $4.09 Million - $8.04 Million
561,702 Added 19.14%
3,496,808 $50.1 Million
Q1 2023

May 05, 2023

BUY
$6.19 - $12.36 $18.2 Million - $36.3 Million
2,935,106 New
2,935,106 $21 Million

Others Institutions Holding PHAT

About Phathom Pharmaceuticals, Inc.


  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $294M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Carlyle Group Inc. Portfolio

Follow Carlyle Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Carlyle Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Carlyle Group Inc. with notifications on news.